David Evans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Evans has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Beverly A. Teicher
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
7 shared publications - Dmitriy Sonkin
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, MD 20850, USA
7 shared publications - Donn G. Wishka
Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland
7 shared publications - Eric C. Polley
Department of Public Health Sciences, University of Chicago, Chicago, IL
7 shared publications - James H. Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, USA
7 shared publications - Jerry Collins
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
7 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 8 (1)
Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo
Late-stage melanoma can metastasize to organs beyond the skin, such as lungs, liver, brain, and bone, resulting in reduced patient survival time. The incidence of melanoma is currently growing worldwide, and novel therapeutic options are needed to prevent its dissemination and to improve therapeutic results. This paper describes the use of small interfering RNA (siRNA) to silence expression of TGFβ1 and VEGFR2 as an alternative approach for melanoma treatment. These two therapeutic targets have been well-documented in tumor immune modulation and tumor angiogenesis within the tumor microenvironment (TME). Two potent siRNA candidates targeting TGFβ1 or VEGFR2 were identified with 100% identity to sequences of mouse, non-human primate (NHP), and humans. The combination of the two siRNAs was formulated with a clinically validated polypeptide nanoparticle (PNP) carrier. This PNP-packaged siRNA formulation, STP355, administered intravenously in mice bearing syngeneic melanoma tumors, demonstrated silencing of both targets and a reduction in tumor growth. STP355 also reduced tumor weight significantly, without the toxicity observed with cisplatin, resulting in prolonged survival of mice compared with this small molecule. It increased immune cell penetration into TME and reduced metastases to the lung. STP355 was more efficacious than, and somewhat additive with, immune checkpoint inhibitory monoclonal antibodies.
- 9 January 2026
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 8 (1)
Open AccessIdentification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo
Late-stage melanoma can metastasize to organs beyond the skin, such as lungs, liver, brain, and bone, resulting in reduced patient survival time. The incidence of melanoma is currently growing worldwide, and novel therapeutic options are needed to prevent its dissemination and to improve therapeutic results. This paper describes the use of small interfering RNA (siRNA) to silence expression of TGFβ1 and VEGFR2 as an alternative approach for melanoma treatment. These two therapeutic targets have been well-documented in tumor immune modulation and tumor angiogenesis within the tumor microenvironment (TME). Two potent siRNA candidates targeting TGFβ1 or VEGFR2 were identified with 100% identity to sequences of mouse, non-human primate (NHP), and humans. The combination of the two siRNAs was formulated with a clinically validated polypeptide nanoparticle (PNP) carrier. This PNP-packaged siRNA formulation, STP355, administered intravenously in mice bearing syngeneic melanoma tumors, demonstrated silencing of both targets and a reduction in tumor growth. STP355 also reduced tumor weight significantly, without the toxicity observed with cisplatin, resulting in prolonged survival of mice compared with this small molecule. It increased immune cell penetration into TME and reduced metastases to the lung. STP355 was more efficacious than, and somewhat additive with, immune checkpoint inhibitory monoclonal antibodies.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessAnalytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Table S1 from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessAnalytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
Analytical Data from Targeted Investigational Oncology Agents (IOA) in the NCI60: A Phenotypic Systems-Based Resource
- Open Access
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcad059
Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors
Upregulation of TGFβ and Cox2 in the tumor microenvironment results in blockade of T-cell penetration into the tumor. Without access to tumor antigens, the T-cell response will not benefit from administration of the immune checkpoint antibodies. We created an intravenous polypeptide nanoparticle that can deliver two siRNAs (silencing TGFβ and Cox2). Systemic administration in mice, bearing a syngeneic orthotopic hepatocellular carcinoma (HCC), delivers the siRNAs to various cells in the liver, and significantly reduces the tumor. At 2 mg/kg (BIW) the nanoparticle demonstrated a single agent action and induced tumor growth inhibition to undetectable levels after five doses. Reducing the siRNAs to 1mg/kg BIW demonstrated greater inhibition in the presence of PD-L1 mAbs. After only three doses BIW, we could still recover a smaller tumor and, in tumor sections, showed an increase in penetration of CD4+ and CD8+ T-cells deeper into the remaining tumor that was not evident in animals treated with non-silencing siRNA. The combination of TGFβ and Cox2 siRNA co-administered in a polypeptide nanoparticle can act as a novel therapeutic alone against HCC and may augment the activity of the immune checkpoint antibodies. Silencing TGFβ and Cox2 converts an immune excluded (cold) tumor into a T-cell inflamed (hot) tumor.
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcad059
Open AccessCodelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors
Upregulation of TGFβ and Cox2 in the tumor microenvironment results in blockade of T-cell penetration into the tumor. Without access to tumor antigens, the T-cell response will not benefit from administration of the immune checkpoint antibodies. We created an intravenous polypeptide nanoparticle that can deliver two siRNAs (silencing TGFβ and Cox2). Systemic administration in mice, bearing a syngeneic orthotopic hepatocellular carcinoma (HCC), delivers the siRNAs to various cells in the liver, and significantly reduces the tumor. At 2 mg/kg (BIW) the nanoparticle demonstrated a single agent action and induced tumor growth inhibition to undetectable levels after five doses. Reducing the siRNAs to 1mg/kg BIW demonstrated greater inhibition in the presence of PD-L1 mAbs. After only three doses BIW, we could still recover a smaller tumor and, in tumor sections, showed an increase in penetration of CD4+ and CD8+ T-cells deeper into the remaining tumor that was not evident in animals treated with non-silencing siRNA. The combination of TGFβ and Cox2 siRNA co-administered in a polypeptide nanoparticle can act as a novel therapeutic alone against HCC and may augment the activity of the immune checkpoint antibodies. Silencing TGFβ and Cox2 converts an immune excluded (cold) tumor into a T-cell inflamed (hot) tumor.
- Open Access
- 7 August 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (11) , 1270-1279
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.
- 7 August 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (11) , 1270-1279
Open AccessTargeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.
- Open Access
- 11 August 2020
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 2 (3) , zcaa016
A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant toxicity for the patient. Genes have been identified that, when silenced by siRNA, synergize with gemcitabine treatment and offer a means of reducing the gemcitabine dosage required for efficacy. However, benefiting from the synergism between the two agents requires that the gemcitabine and siRNA penetrate the same cells. To ensure co-delivery, we incorporated gemcitabine covalently within siRNAs against targets synergistic with gemcitabine (CHK1 or RAD17). We demonstrated that specific bases within an siRNA can be replaced with gemcitabine to increase efficacy. The result is a single drug molecule that simultaneously co-delivers gemcitabine and a synergistic siRNA. The siRNA–gemcitabine constructs demonstrate a 5–30-fold improvement in potency compared with gemcitabine alone. Co-delivering a CHK1 siRNA–gemcitabine construct together with a WEE1 siRNA resulted in a 10-fold improvement in IC50 compared with gemcitabine alone. These constructs demonstrate efficacy across a wide array of pancreatic tumor cells and may represent a novel therapeutic approach for treating pancreatic cancer.
- 11 August 2020
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 2 (3) , zcaa016
Open AccessA novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
The non-nucleoside analog gemcitabine has been the standard of care for treating pancreatic cancer. The drug shows good potency in pancreatic cancer cells in vitro but, due to poor bioavailability, requires administration in large doses by infusion and this systemic exposure results in significant toxicity for the patient. Genes have been identified that, when silenced by siRNA, synergize with gemcitabine treatment and offer a means of reducing the gemcitabine dosage required for efficacy. However, benefiting from the synergism between the two agents requires that the gemcitabine and siRNA penetrate the same cells. To ensure co-delivery, we incorporated gemcitabine covalently within siRNAs against targets synergistic with gemcitabine (CHK1 or RAD17). We demonstrated that specific bases within an siRNA can be replaced with gemcitabine to increase efficacy. The result is a single drug molecule that simultaneously co-delivers gemcitabine and a synergistic siRNA. The siRNA–gemcitabine constructs demonstrate a 5–30-fold improvement in potency compared with gemcitabine alone. Co-delivering a CHK1 siRNA–gemcitabine construct together with a WEE1 siRNA resulted in a 10-fold improvement in IC50 compared with gemcitabine alone. These constructs demonstrate efficacy across a wide array of pancreatic tumor cells and may represent a novel therapeutic approach for treating pancreatic cancer.